Decline in Pharma Business Leads to 76 Percent Drop in Q2 Revenues for Response Genetics | GenomeWeb

NEW YORK (GenomeWeb News) – Response Genetics' second-quarter revenues plummeted 76 percent year over year on a drop-off in the company's pharmaceutical client sales, the Los Angeles-based molecular diagnostics firm reported today.

Total revenues for the three months ended June 30 were $3.8 million, compared to $6.7 million a year ago. While ResponseDX revenue fell $151,000 from a year ago, pharmaceutical client revenue fell by more than $2.7 million from a year ago, the firm said, adding that the drop was expected.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: a sequencing-based screen of Lyme disease-causing pathogen, the range of animals bitten by Anopheles darling mosquitoes in Peru, and more.

An NC State researcher is exploring the use of CRISPR-Cas3 as an anti-microbial, Gizmodo reports.

The Earth BioGenome Project plans to sequence all life on Earth, according to ScienceInsider.

For those who are concerned about Trump administration actions related to science, a new column in Scientific American has suggestions for ways to fight back.